Advanced Coronary Diagnostics for Everyone
Revolutionizing FFR for optimal patient care and outcomes.
About Physiology ONE
Our Mission
Our mission is to future-proof fractional flow reserve (FFR) as a real-time invasive gold standard by renovating its diagnostic performance to accommodate a broader and more complex patient population, like the elderly and acute coronary syndrome (ACS) patients. At present, the utilization of coronary physiology is multiple times lower in older adults despite a disproportionate share of overall PCI mortality and pronounced outcomes benefit with physiology-guided operative decisions. We believe better optimization of FFR by measuring at the end-diastolic phase and correcting for left ventricular end-diastolic pressure (LVEDP) would add new performance to an old gold standard making it a more sensitive and a more reliable measure of myocardial ischemia. This alone unlocks a new wave of state-of-the-art PCI and algorithmic intravascular imaging (IVI) on previously masked ischemic lesions when measured by today’s physiological parameters including non-hyperemic and non-invasive surrogates.
With a nod to new agentic compute and multimodal AI workloads seen in rapidly emerging non-invasive LVEDP algorithms, we hold key IP to recalibrate all existing commercial indices including FFR, non-hyperemic pressure ratios (NHPRs), non-invasive FFR, including FFRCT and angiography-based FFR, and index of microcirculatory resistance (IMR). This allows us to have an immediate impact in vulnerable and underserved populations like elderly patients with elevated left filling pressure as “a rising tide that lifts all boats”.
At the same time, to expand performance in today’s standard of care diagnostic modality, we implement a simple phase-shift to end-diastole and push ischemia detection limits with continuous phase-matched invasive left ventricular pressure and ECG measurements trained by multimodal AI to latest positron emission tomography-based macrovascular and microvascular perfusion. With the next generation AI-powered end-diastolic ratio or AI-iEDR Ultra® on portable NVIDIA workstation, we look forward to launching the very first superiority in outcomes randomized controlled trial (RCT) in elderly and complex PCI patients to show improvement over traditional FFR or NHPR.
Copyright © 2025 Physiology ONE - All Rights Reserved.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.